The South Florida Business Journal reported on the boom in compounded GLP-1s and Scott explained...
Pharmaceutical Technology lets us tell ’em how we really feel about Novo asking the FDA to put semaglutide on the Demonstrably Difficult to Compound list.
Alliance for Pharmacy Compounding’s CEO Scott Brunner did not hold back in a statement following Novo Nordisk’s request, citing “desperation” and “ridiculous claims” made by the drugmaker.
The South Florida Business Journal reported on the boom in compounded GLP-1s and Scott explained...
UK-based pharmaphorum is covering the GLP-1 issue on this side of the pond — specifically Lilly’s...
Our comment to FDA about its use of the Pharmacy Compounding Advisory Committee (PCAC) was covered...